Basel, 25 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has launched the AVENIO Tumor Tissue CGP Kit. The Kit complements the current CGP portfolio offered by Roche and Foundation Medicine and allows laboratories to expand their oncology research in-house. Ultimately, a future version of the kit may lead to additional resources for clinicians to use in the diagnosis and treatment of cancer.

Attachments

  • Original document
  • Permalink

Disclaimer

Roche Holding AG published this content on 25 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 October 2021 05:03:07 UTC.